Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae035 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Aaron P Mitchell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Hauptthemen laut MEDLINE: Medicaid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AHRQ HHS, Healthcare Research and Quality.
Abstract (Originalsprache)
Background
Because the markups on cancer drugs vary by payor, providers’ financial incentive to use high-price drugs is differential according to each patient’s insurance type. We evaluated the association between patient insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Materials and Methods We linked cancer registry, administrative claims, and demographic data for individuals diagnosed with cancer in North Carolina from 2004 to 2011, with either commercial or Medicaid insurance. We selected cancers with multiple FDA-approved, guideline-recommended chemotherapy options and large price differences between treatment options: advanced colorectal, lung, and head and neck cancer. The outcome was a receipt of a higher-priced option, and the exposure was insurer: commercial versus Medicaid. We estimated risk ratios (RRs) for the association between insurer and higher-priced treatment using log-binomial models with inverse probability of exposure weights.
Results
Of 812 patients, 209 (26%) had Medicaid. The unadjusted risk of receiving higher-priced treatment was 36% (215/603) for commercially insured and 27% (57/209) for Medicaid insured (RR: 1.31, 95% CI: 1.02-1.67). After adjustment for confounders the association was attenuated (RR: 1.15, 95% CI: 0.81-1.65). Exploratory subgroup analysis suggested that commercial insurance was associated with increased receipt of higher-priced treatment among patients treated by non-NCI-designated providers (RR: 1.53, 95% CI: 1.14-2.04).
Conclusions
Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
- Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, United States.
ORCID-Profile: Aaron P Mitchell
Förderung
- NCI NIH HHS
- AHRQ HHS
- Healthcare Research and Quality
Zitieren
APA
Mitchell, A. P., Kinlaw, A. C., Peacock-Hinton, S., Dusetzina, S. B., Winn, A. N., Sanoff, H. K., & Lund, J. L. (2024). Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments. The Oncologist. https://doi.org/10.1093/oncolo/oyae035
Vancouver
Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Winn AN, Sanoff HK, et al. Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments. The Oncologist. 2024. doi:10.1093/oncolo/oyae035
BibTeX
@article{Mitchell2024,
author = {Mitchell, Aaron P and Kinlaw, Alan C and Peacock-Hinton, Sharon and Dusetzina, Stacie B and Winn, Aaron N and Sanoff, Hanna K and Lund, Jennifer L},
title = {Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae035}
}
EUVIMED